• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
  • IgAN Care
  • About Us
        • MM About

          • About Us
          • Leadership Team
          • Board of Directors
          • Medical & Scientific Advisory Board
        • MM About 2

          • Articles
          • Sponsors
          • Our Partners
  • Resources
        • MM – Resource 1

          • What is IgAN
          • Diagnosis
          • Understanding Your Lab Results
          • Understanding Your Biopsy
        • MM – Resource 2

          • IgAN Info
          • Faces of IgAN
          • IgAN Risk Quiz
          • American Asian Info
          • FAQ
          • IgAN Cookbook
        • MM – Resource 3

          • Support Options
          • Apply for Patient Aid
          • Patient Support
        • MM – Resource 4

          • Learning & Resources
          • Webinars
          • Guides & Fact Sheets
          • Nutrition & Recipes
          • Mental Health
          • Learn About Insurance
          • Podcasts
          • Treatment Options
  • Research
        • MM Research

          • IgA Nephropathy Studies
          • IgA Nephropathy Research
        • Clinical Trials

          • Clinical Trials
  • Join
        • MM – Join 1

          • Events
          • Calendar of Events
          • IgA Nephropathy Day
          • Rare Disease Day
        • MM – Join 2

          • Become a Member
          • Ambassador Program
          • Ways to Give
  • For Health
    Care Professionals
    Hidden for now, remove the “hide” class when available.
  • Donate
  • IgAN Care

Clinical Trials

The IgA Nephropathy Foundation is working with the partners below to provide our patients access to breakthrough clinical trials. Patient participation is the key to finding treatment and the ultimate cure for IgA Nephropathy. Read more about each trial below to see if you are eligible.

Open Trials

Phase 2 ALXN1210-NEPH-202 Study

Currently Open

Now Enrolling People with Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) For A Research Study Phase 2 ALXN1210-NEPH-202 Study (clinicaltrials.gov NCT04564339) Purpose of Study The purpose of this clinical …

Read morePhase 2 ALXN1210-NEPH-202 Study

Alpine Immune Sciences

Currently Open

The RUBY-3 Study: This clinical study is evaluating povetacicept, a new investigational drug, in people with IgA nephropathy (IgAN) and other autoimmune diseases of the kidney. Povetacicept is designed to reduce the inflammation and harmful antibodies that damage the kidneys, thereby reducing or possibly reversing kidney damage.

Read moreAlpine Immune Sciences

The ASSIST Study

Have you been diagnosed with IgA nephropathy? The ASSIST study is a phase 2, randomized, placebo-controlled, cross-over study of atrasentan* in adults with IgA nephropathy (IgAN). The ASSIST study is …

Read moreThe ASSIST Study

APPLAUSE-IgAN

Currently Open

APPLAUSE-IgAN is a Phase 3 global clinical trial that will look at the effects of an investigational drug, iptacopan (LNP023), in people with IgAN. The trial will study the effects of iptacopan (LNP023) on reducing inflammation and kidney damage in people with IgAN.

Read moreAPPLAUSE-IgAN

The BEYOND Study

Are you living with IgA nephropathy? The BEYOND study is a phase 3, randomized, double-blind, placebo-controlled study of zigakibart(BION-1301) in adults with IgA nephropathy (IgAN). The BEYOND study is a …

Read moreThe BEYOND Study

EPPIK clinical study

Currently Open

Travere Therapeutics is evaluating a study medication called sparsentan to determine if it will be a safe and effective treatment that helps slow the decline of kidney function in children living with rare kidney diseases.

Read moreEPPIK clinical study

RestoreD Study

The RestoreD Study is a clinical research study evaluating an oral investigational medication, ALXN2050, that may help participants manage their Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) symptoms.

Read moreRestoreD Study

VISIONARY: A Phase 3 clinical trial

Currently Open

VISIONARY: A Phase 3 clinical trial of sibeprenlimab for adults with IgA Nephropathy. Targeting a brighter future for IgAN patients.

Read moreVISIONARY: A Phase 3 clinical trial

ORIGIN 3 Phase 3 Clinical Trial

Currently Open

ORIGIN 3 is a Phase 3 clinical trial researching an investigational medication called atacicept in adults with IgAN. The trial will measure the effectiveness of atacicept at improving kidney function by preventing damage caused by the buildup of IgA in the kidneys.

Read moreORIGIN 3 Phase 3 Clinical Trial
Donate
  • Facebook
  • Twitter
  • Instagram
  • YouTube

Quick Links

  • About Us
  • Patient Resources
  • Research
  • Contact Us
  • Join Our Efforts

Contact Us

(848) 298-4618

(732) 681-3462

PO Box 1322 Wall, NJ 07727

© 2023 All Rights Reserved.

May 14, Sunday: Mother’s Day & IgA Nephropathy Awareness Day

The IgAN Foundation was sparked by a mother’s love and has grown into a community sharing crucial resources and working toward a cure. This day kicks off a week of celebrating the IGA Nephropathy family all week!

May 15, Monday: Mindfulness

IgA Nephropathy can be challenging and mindfulness is an important part of caring for yourself. Take a moment today and implement a mindfulness practice, meditate, or take a few moments in reflection to check in with yourself.

May 16, Tuesday: Share Your Story

On this day, the Foundation will share the video with Warrior stories compiled (submit yours here if you haven’t yet). We encourage you to also share your own photos and videos from moments along your journey!

May 17, Wednesday: Wellness

What are you doing to feel well today? IgA Nephropathy can sometimes make life feel uncontrollable, but there are some things we can control, for example:

  • Enjoyable movement (a stretch, a walk, dancing to a favorite song)
  • Eating food that’s right for us individually
  • Checking in with ourselves
  • Meditating

May 18, Thursday: Thank those who care

Between care teams, care partners, and medical providers, a lot goes into the care that sustains us as we live with IgA Nephropathy. Take this opportunity to express your appreciation to them!

May 19, Saturday: Rally cry

When the IgA Nephropathy Foundation was created, there were no resources to treat IgA Nephropathy. Now, there are 2 approved FDA treatments and many clinical trials in the works. Our community is strong and full of hope— here’s to even more progress in the future!

May 20, Saturday: Celebration! 

We’ll be hosting an in-person celebration (details to come). We’ll miss you if you can’t make it, but please take the time to celebrate however works for you — wearing your IgAN Foundation sunglasses, spending time with loved ones, etc. — just be sure to share a photo and tag us!

References

  • Hall, Y.N., Fuentes, E.F., Chertow, G.M. et al. Race/ethnicity and disease severity in IgA nephropathy. BMC Nephrol 5, 10 (2004). https://doi.org/10.1186/1471-2369-5-10
  • Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, et al. (2012) Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLoS Genet 8(6): e1002765. doi:10.1371/journal.pgen.1002765